Zoetis Inc. (ZTS) Stock News

Zoetis stock declined 1.18% to $81.03, underperforming the S&P 500's 0.52% loss. Despite a strong 16.69% monthly gain, the company faces headwinds with projected Q3 EPS down 11.18% and full-year earnings expected to decline 4.21%. The stock holds a Zacks Rank #4 (Sell) rating, though it trades at a valuation discount to its industry peers.

Zoetis (ZTS) gained 2.37% in the latest session, outperforming the S&P 500's 0.6% gain. However, the animal health company faces headwinds with forecasted EPS declining 10.59% and revenue expected to drop 3.66% in the upcoming quarter. The stock holds a Zacks Rank of #4 (Sell) with no recent estimate revisions, and trades at a Forward P/E of 11.78, below its industry average.

Zoetis (ZTS) ended trading at $69.10, down 1.05% from the previous day and 8.32% over the past month. The animal health company faces a negative earnings outlook with forecasted EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The stock has been assigned a Zacks Rank of #5 (Strong Sell), though it trades at a discount to its industry average with a Forward P/E of 11.26.

Zoetis stock declined 2.22% to $71.40, underperforming the broader market gains. The animal health company faces headwinds with projected EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The company holds a Zacks Rank of #5 (Strong Sell) despite trading at a Forward P/E discount to its industry average.

Class action lawsuits have been filed against AeroVironment, Calix, Zoetis, and Lucid Group, alleging that company executives made materially false statements and failed to disclose material adverse facts about their businesses. The lawsuits cover various issues including understated competition, supply chain problems, declining product adoption, and manufacturing disruptions. Lead plaintiff deadlines range from July 27-28, 2026.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 2025 to May 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining sales in dermatology products Apoquel and Cytopoint. Investors who purchased securities during this period may be eligible for compensation.

A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and declining sales of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. The deadline to file a lead plaintiff motion is July 27, 2026.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period from January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities during this period may be eligible for compensation. The lead plaintiff deadline is July 27, 2026.

A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements about product adoption during the class period of January 14, 2025 through May 6, 2026. The lawsuit alleges the company misrepresented the performance of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. Zoetis's stock fell 21.5% on May 7, 2026, following disappointing first quarter results showing significant decline in its Companion Animal business. Investors have until July 27, 2026, to file for lead plaintiff status.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during the period of January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its flagship products Librela, Simparica Trio, and dermatology treatments Apoquel and Cytopoint due to safety concerns, competition, and market share losses. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 27, 2026 lead plaintiff deadline.

Zoetis Inc. faces a securities class action lawsuit covering January 14, 2025 through May 6, 2026, with CEO Kristin Peck and CFO Wetteny Joseph named as individual defendants. The lawsuit alleges they certified misleading statements about companion animal product performance while safety concerns and competitive losses mounted. Zoetis shares fell 21.5% to $87.31 on May 7, 2026 following corrective disclosures. The lead plaintiff deadline is set for July 27, 2026.

Rosen Law Firm is notifying Zoetis Inc. investors who purchased securities between January 14, 2025 and May 6, 2026 of an important July 27, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Zoetis made false statements about market share and sales growth while failing to disclose weakening adoption of flagship products Librela and Simparica Trio, as well as market share losses in dermatology products due to FDA safety warnings and increased competition.

Glancy Prongay Wolke & Rotter LLP announced a securities fraud class action lawsuit against Zoetis Inc., alleging the company made materially false statements and failed to disclose material adverse facts about its business. The lawsuit covers investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026. The company's stock declined significantly following three earnings announcements that revealed weakened demand in its Companion Animal portfolio, increased competition, and reduced growth outlooks. The deadline to file a lead plaintiff motion is July 27, 2026.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025 and May 6, 2026. The lawsuit alleges that Zoetis made false and misleading statements about market share growth and product adoption while failing to disclose significant market share losses in key products including Librela, Simparica Trio, Apoquel, and Cytopoint due to increased competition and FDA safety warnings. The deadline to apply as lead plaintiff is July 27, 2026.

Rosen Law Firm has filed securities class action lawsuits against Zoetis Inc. and ChampionX Corporation. The Zoetis lawsuit alleges the company made false statements about market share and product adoption while failing to disclose weakening sales of key products like Librela and Simparica Trio due to safety concerns and increased competition. The lead plaintiff deadline for the Zoetis case is July 27, 2026.

The Schall Law Firm has filed a class action lawsuit against Zoetis Inc. for alleged securities fraud, claiming the company made false and misleading statements regarding its products. The lawsuit alleges that Zoetis failed to disclose weakening prescription growth for Librela following FDA safety warnings about neurological complications in dogs, as well as market share losses for its Trio, Apoquel, and Cytopoint products. Investors who purchased securities between January 14, 2025 and May 6, 2026 are encouraged to join the case.

Rosen Law Firm is notifying Zoetis Inc. investors of a securities class action lawsuit covering purchases between January 14, 2025 and May 6, 2026. The lawsuit alleges that Zoetis made false statements about market share and sales growth while failing to disclose weakening adoption of flagship products Librela and Simparica Trio, as well as market share losses in dermatology products. The lead plaintiff deadline is July 27, 2026.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 2025 to May 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 27, 2026 deadline.

A securities fraud class action lawsuit has been filed against Zoetis Inc. for allegedly making materially false statements about product adoption during the period from January 14, 2025 through May 6, 2026. The complaint alleges the company misrepresented the performance of key products including Librela, Simparica Trio, Apoquel, and Cytopoint. Zoetis's stock fell 21.5% on May 7, 2026, following disappointing first quarter results showing significant decline in its Companion Animal business. Investors have until July 27, 2026, to seek lead plaintiff status.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. The lead plaintiff deadline is July 27, 2026.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Calix (CALX), AeroVironment (AVAV), Zoetis (ZTS), and Lucid Group (LCID). The lawsuits allege that defendants made false or misleading statements regarding their business operations, financial prospects, and market conditions. Lead plaintiff deadlines range from July 27-28, 2026.

Rosen Law Firm reminds investors in Zoetis Inc. (ZTS) of the July 27, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Zoetis made false statements about market share growth and product adoption during the period from February 14, 2025 to May 6, 2026. Specifically, the firm claims Zoetis failed to disclose weakening demand for its Librella pain treatment due to FDA safety warnings, loss of market share for Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 27, 2026 lead plaintiff deadline.

Zoetis Inc. faces a securities class action lawsuit alleging the company misled investors about its Companion Animal portfolio's competitive strength and growth prospects. The stock collapsed 21.5% ($23.91 per share) after four corrective disclosures revealed that key products like Librela, Simparica Trio, and Apoquel/Cytopoint underperformed projections due to safety concerns, intensified competition, and declining veterinarian confidence. The lead plaintiff deadline is July 27, 2026, and the class period covers January 14, 2025 to May 6, 2026.

Rosen Law Firm is encouraging investors who purchased Zoetis Inc. securities between January 14, 2025 and May 6, 2026 to join a class action lawsuit. The lawsuit alleges that Zoetis made false statements about market share and sales growth while failing to disclose weakening adoption of key products like Librela due to FDA safety warnings, market share losses in Simparica Trio and dermatology products, and declining veterinarian adoption. The lead plaintiff deadline is July 27, 2026.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies. Calix faces allegations of misleading statements regarding margin pressures from memory component costs. AeroVironment is accused of overstating business prospects amid competitive threats. Zoetis is alleged to have concealed weakening demand for key products due to safety concerns and market competition. Lucid Group is charged with failing to disclose supplier quality issues affecting vehicle deliveries. All cases have lead plaintiff deadlines in late July 2026.

A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products. The lawsuit claims the company failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 may be entitled to compensation. The lead plaintiff deadline is July 27, 2026.

Class action lawsuits have been filed against Calix, AeroVironment, and Zoetis for allegedly making false or misleading statements about their financial performance and business prospects. Investors have until July 27, 2026 to file lead plaintiff motions in these securities fraud cases.

Rosen Law Firm has filed class action lawsuits against Zoetis Inc., Babcock & Wilcox Enterprises, and Stellantis N.V. on behalf of investors who purchased securities during specified periods. The Zoetis lawsuit alleges the company made false statements about market share and product adoption while failing to disclose weakening sales of key products including Librela, Simparica Trio, and dermatology treatments due to safety concerns and increased competition. Investors are encouraged to secure counsel before the July 27, 2026 deadline to serve as lead plaintiff.

Robbins Geller announces a class action lawsuit against Zoetis Inc. for alleged securities violations. The lawsuit claims Zoetis made false statements about its flagship products including Librela, Simparica Trio, Apoquel, and Cytopoint, failing to disclose weakening demand, market share losses to competitors, and increased competitive pressures. Investors who purchased ZTS securities between January 14, 2025 and May 6, 2026 can seek appointment as lead plaintiff by July 27, 2026.